<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01617070</url>
  </required_header>
  <id_info>
    <org_study_id>USC Kuvan Melatonin</org_study_id>
    <nct_id>NCT01617070</nct_id>
  </id_info>
  <brief_title>Effects of Kuvan on Melatonin Secretion</brief_title>
  <official_title>Pilot Study to Evaluate Melatonin Secretion as a Marker of Decreased Serotonin in Individuals With PKU: Evaluation of the CNS Effects of Tetrahydrobiopterin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the effect of tetrahydrobiopterin (Kuvan) and Large Neutral Amino Acid
      (LNAA) therapy on melatonin and dopamine levels in individuals with Phenylketonuria (PKU).
      The investigators hypothesize that Kuvan therapy will improve melatonin secretion and urine
      dopamine levels to some extent. However significantly greater responses in melatonin and
      dopamine secretions may be observed with combined treatment with Kuvan and supplementation of
      LNAA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Phenylketonuria (PKU) is a genetic condition due to missing one of the key
      enzymes of phenylalanine (Phe) degradation. The missing enzyme is phenylalanine hydroxylase
      (PAH). Because of the deficiency of the enzyme, plasma Phe is highly elevated compared with
      other plasma amino acids. This abnormal ratio i.e., Phe vs. each of the other large neutral
      amino acids (LNAA) which are transported into the brain as precursors of neurotransmitters
      through the common transporter LAT1, is likely to contribute to neurotransmitter deficiencies
      in individuals with PKU. Patients who do not restrict Phe intake develop mental retardation
      and neuropsychological disorders. Treatment of PKU has been historically limited to
      restriction of Phe intake, meaning protein restriction.

      The FDA recently approved a new medication, Kuvan, a synthetic form of tetrahydrobiopterin
      (BH4) manufactured by BioMarin Pharmaceutical Inc., for patients with PKU. Kuvan is a
      cofactor for PAH, tyrosine hydroxylase, and tryptophan hydroxylase. Patients with PKU
      typically undergo a month-long trial of Kuvan to determine if they are responders to the
      drug, meaning blood phenylalanine drops by more than 30 percent. Those who are not responders
      do not usually continue Kuvan, however our recent study (HS 08-00147) showed that classical
      PKU patients who are not Kuvan responders demonstrated improvement in their maladaptive
      behaviors, suggesting some effects of Kuvan in the CNS system without reducing blood
      phenylalanine concentrations (Moseley et al, manuscript under preparation). Seven subjects
      who did not respond to Kuvan with lower blood Phe levels had significant increases in blood
      tyrosine after 6 months (p=0.015), along with improvement in the Vineland Internalizing and
      Overall Maladaptive Behavior Indexes at 12 months (p=0.032 and 0.049, respectively). Kaufman
      reported that Kuvan at dose of 20 mg/kg/day increased CSF BH4 levels (1). Based on these
      observations, it is likely that Kuvan has some effects on neurotransmitter metabolism.

      Supplementation of large neutral amino acids (LNAA) as a medical food has been used in Europe
      for the past 25 years and it is believed to be effective in treating patients with PKU. In
      the article by Shindeler et al. (2), 16 individuals (7 males and 9 females; age 11y to 45 y)
      participated in the study which consisted 4 weeks wash-out and 4 two-weeks stages (on
      phenylalanine restricted diet and with/without LNAA, and on no phenylalanine restricted diet
      and with/without LNAA). No specific adverse effects are reported in the article. Large
      neutral amino acid therapy for the treatment of PKU has been done in the past (3). LNAA is
      used primarily for adolescents and adults who cannot adhere to the standard phe-restricted
      diet. LNAA treatment has been approved for PKU patients just like other special formulas. Our
      previous studies have demonstrated deficiency of serotonin in the brain, as evidenced by low
      nocturnal melatonin secretion and reduced urine dopamine compared to controls, and that
      supplementation with LNAA improves, but does not normalize these markers.

      Rationale: Patients with PKU are thought to be deficient in tyrosine and tryptophan in the
      brain tissue level because of the abnormal phe/tyrosine and phe/tryptophan ratios. Previous
      studies showed low serotonin levels in cerebrospinal fluid in PKU individuals and some
      improvement was observed after tryptophan supplementation (4). Our prior study suggested
      deficiency of tryptophan in the brain tissue was demonstrated by low nocturnal melatonin
      secretion and 6-sulfatoxymelatonin, which is a stable metabolite of melatonin (5). LNAA
      supplementation resulted in some improvement in melatonin secretion, however, melatonin
      secretion in patients with PKU on LNAA was still significantly lower than the control group.
      Supplementation of Kuvan may activate the brain tyrosine and tryptophan hydroxylases (6),
      resulting in improvement of nocturnal melatonin secretion and urine melatonin and dopamine
      concentrations. By supplementing LNAA increased amount of neurotransmitter precursor amino
      acids will be transported into the brain and activated brain tyrosine and tryptophan
      hydroxylases by Kuvan will act on these precursors to produce neurotransmitters, i.e.,
      serotonin and dopamine. These synergistic effects may increase melatonin and dopamine levels
      to closer to the control levels.

      Aims of the Study: To show scientific evidence of improvement in metabolism of
      neurotransmitters including serotonin and dopamine in patients with PKU treated with LNAA
      only, Kuvan only, and Kuvan and LNAA.

      Objectives: This investigator initiated study has three objectives: (1) To evaluate if
      tetrahydrobiopterin (Kuvan) supplementation has beneficial effects on melatonin secretion and
      urine dopamine levels in individuals with PKU when they are and are not treated with large
      neutral amino acids; (2) To demonstrate synergistic effects of LNAA supplementation and Kuvan
      therapy in improvement of neurotransmitter metabolism in individuals with PKU; and (3) To
      gather pilot information necessary to design a larger, multicenter trial of these
      interventions, should results of these pilot studies indicate further study is warranted.

      Study Methodology: This study will be conducted in adult patients with PKU in four 4-week
      phases: phase I (large neutral amino acid/LNAA), phase II (Washout), phase III (Kuvan only)
      and phase IV (Kuvan and LNAA). Kuvan supplementation will be adjusted to provide 20
      mg/kg/day. LNAA therapy is adjusted to the manufacturer's instruction (total tablets of LNAA
      is 1/2 X BW kg). On the last day of each phase, subjects will stay approximately 14 to 18
      hours overnight at the CTU at USC University Hospital. Blood specimens will be collected
      every 2 hours from 7:00 pm to 7:00 am. First void urine will be collected on the day of
      discharge (patients will be asked to void urine at 11:00 pm and the first void urine will be
      collected).

      Blood will be collected in a red top tube (5 ml) through an IV line which is saline locked
      during the study period. Avoid hemolysis by collecting blood through an IV line into a
      reasonably large peripheral vein. Blood will be left to clot for 45 minutes at room
      temperature (18-28 C) and protected from light (a dim flash light or a yellow light &lt; 100
      lux). Serum will be collected and stored at - 20 C until they are subjected to analysis for
      plasma melatonin and plasma amino acids. Urine 20 ml first void sample will be collected into
      two plain tubes (10 ml per each tube) and stored in a deep freezer (-20 C) until subjected to
      be analyzed for dopamine and 6-sulfatoxymelatonin.

      This is an open-labeled study. During all four 4-week phases, subjects will remain on their
      protein-restricted diet. LNAA tablets are not considered a medicine, but are under the
      category of medical foods; examples include low protein foods. LNAA tablets will be provided
      by the LNAA manufacture (Applied Nutrition). Kuvan will be taken per orally with breakfast
      and LNAA tablets will be taken with meals three times per day.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Melatonin at the End of 4 Weeks</measure>
    <time_frame>measured every 4 weeks up to 16 weeks</time_frame>
    <description>Evaluated for each subject under 4 conditions (washout, LNAA only, Kuvan only and LNAA+Kuvan)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine 6-sulfatoxymelatonin at the End of 4 Weeks</measure>
    <time_frame>measured every 4 weeks up to 16 weeks</time_frame>
    <description>Evaluated for each subject under 4 conditions (washout, LNAA only, Kuvan only and LNAA+Kuvan)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Dopamine at the End of 4 Weeks</measure>
    <time_frame>measured every 4 weeks up to 16 weeks</time_frame>
    <description>Evaluated for each subject under 4 conditions (washout, LNAA only, Kuvan only and LNAA+Kuvan)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Phenylketonuria (PKU)</condition>
  <arm_group>
    <arm_group_label>LNAA, washout, Kuvan, and LNAA+Kuvan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One group of 12 subjects, each under 4 conditions (each phase is 4 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kuvan</intervention_name>
    <description>Dosed at 20 mg/kg; PO; Phase 3, Phase 4</description>
    <arm_group_label>LNAA, washout, Kuvan, and LNAA+Kuvan</arm_group_label>
    <other_name>Tetrahydrobiopterin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Large Neutral Amino Acid Therapy</intervention_name>
    <description>Dosed by weight: weight x .5 = total tablets per day; PO; Phase 1, Phase 4; taken with food</description>
    <arm_group_label>LNAA, washout, Kuvan, and LNAA+Kuvan</arm_group_label>
    <other_name>LNAA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult English-speaking patients who have confirmed PKU, and have tolerated Kuvan
             therapy at 20 mg/kg/day in the past, and are currently on the LNAA supplements will be
             considered as candidates for the study.

          -  Subjects must be able to stop LNAA therapy for 4 weeks.

          -  This will be determined by the subjects themselves, based on their past personal
             experiences.

        Exclusion Criteria:

          -  Individuals who have never taken Kuvan, who have never been on LNAA therapy, who are
             under the age of 18, or who do not speak English will be excluded.

          -  Subjects who cannot stop LNAA therapy for 4 weeks will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shoji Yano, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>USC Keck School of Medicine, Dept. of Pediatrics, Genetics Division</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Keck School of Medicine, Clinical Trials Unit at Keck Medical Center of USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kaufman S, Kapatos G, McInnes RR, Schulman JD, Rizzo WB. Use of tetrahydropterins in the treatment of hyperphenylalaninemia due to defective synthesis of tetrahydrobiopterin: evidence that peripherally administered tetrahydropterins enter the brain. Pediatrics. 1982 Sep;70(3):376-80.</citation>
    <PMID>7110811</PMID>
  </reference>
  <reference>
    <citation>Schindeler S, Ghosh-Jerath S, Thompson S, Rocca A, Joy P, Kemp A, Rae C, Green K, Wilcken B, Christodoulou J. The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study. Mol Genet Metab. 2007 May;91(1):48-54. Epub 2007 Mar 23.</citation>
    <PMID>17368065</PMID>
  </reference>
  <reference>
    <citation>Lou H. Large doses of tryptophan and tyrosine as potential therapeutic alternative to dietary phenylalanine restriction in phenylketonuria. Lancet. 1985 Jul 20;2(8447):150-1.</citation>
    <PMID>2862338</PMID>
  </reference>
  <reference>
    <citation>Nielsen JB, Lou H, GÃ¼ttler F. Effects of diet discontinuation and dietary tryptophan supplementation on neurotransmitter metabolism in phenylketonuria. Brain Dysfunction 1:51-56. 1988.</citation>
  </reference>
  <reference>
    <citation>Zimmermann RC, McDougle CJ, Schumacher M, Olcese J, Heninger GR, Price LH. Urinary 6-hydroxymelatonin sulfate as a measure of melatonin secretion during acute tryptophan depletion. Psychoneuroendocrinology. 1993;18(8):567-78.</citation>
    <PMID>8127947</PMID>
  </reference>
  <reference>
    <citation>Katz I, Lloyd T, Kaufman S. Studies on phenylalanine and tyrosine hydroxylation by rat brain tyrosine hydroxylase. Biochim Biophys Acta. 1976 Oct 11;445(3):567-78.</citation>
    <PMID>9989</PMID>
  </reference>
  <results_reference>
    <citation>Yano S, Moseley K, Fu X, Azen C. Evaluation of Tetrahydrobiopterin Therapy with Large Neutral Amino Acid Supplementation in Phenylketonuria: Effects on Potential Peripheral Biomarkers, Melatonin and Dopamine, for Brain Monoamine Neurotransmitters. PLoS One. 2016 Aug 11;11(8):e0160892. doi: 10.1371/journal.pone.0160892. eCollection 2016.</citation>
    <PMID>27513937</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2012</study_first_submitted>
  <study_first_submitted_qc>June 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2012</study_first_posted>
  <results_first_submitted>November 8, 2016</results_first_submitted>
  <results_first_submitted_qc>November 8, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 18, 2016</results_first_posted>
  <last_update_submitted>November 8, 2016</last_update_submitted>
  <last_update_submitted_qc>November 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Shoji Yano</investigator_full_name>
    <investigator_title>M.D., Ph.D</investigator_title>
  </responsible_party>
  <keyword>Tetrahydrobiopterin</keyword>
  <keyword>Kuvan</keyword>
  <keyword>Phenylketonuria (PKU)</keyword>
  <keyword>Large Neutral Amino Acids</keyword>
  <keyword>Serotonin</keyword>
  <keyword>Dopamine</keyword>
  <keyword>Melatonin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylketonurias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
    <mesh_term>Serotonin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>LNAA, washout, Kuvan, and LNAA+Kuvan
One group of 10 subjects, each under 4 conditions (each phase is 4 weeks)
Kuvan: Dosed at 20 mg/kg; PO; Phase 3, Phase 4
Large Neutral Amino Acid Therapy: Dosed by weight: weight x .5 = total tablets per day; PO; Phase 1, Phase 4; taken with food</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>LNAA (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>BH4 Therapy (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>BH4 and LNAA (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>started medication interfere with study</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>LNAA, washout, Kuvan, and LNAA+Kuvan
One group of 10 subjects, each under 4 conditions (each phase is 4 weeks)
Kuvan: Dosed at 20 mg/kg; PO; Phase 3, Phase 4
Large Neutral Amino Acid Therapy: Dosed by weight: weight x .5 = total tablets per day; PO; Phase 1, Phase 4; taken with food</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Melatonin at the End of 4 Weeks</title>
        <description>Evaluated for each subject under 4 conditions (washout, LNAA only, Kuvan only and LNAA+Kuvan)</description>
        <time_frame>measured every 4 weeks up to 16 weeks</time_frame>
        <population>Participates who completed all phases were measured.</population>
        <group_list>
          <group group_id="O1">
            <title>LNAA</title>
            <description>LNAA
Large Neutral Amino Acid Therapy: Dosed by weight: weight x .5 = total tablets per day; PO; Phase 1, Phase 4; taken with food</description>
          </group>
          <group group_id="O2">
            <title>Washout</title>
            <description>no Kuvan or LNAA or any medical food products. Limited protein intake diet.</description>
          </group>
          <group group_id="O3">
            <title>BH4 (Kuvan)</title>
            <description>Kuvan (BH4): Dosed at 20 mg/kg; PO; Phase 3, Phase 4</description>
          </group>
          <group group_id="O4">
            <title>BH4 and LNAA</title>
            <description>Kuvan: Dosed at 20 mg/kg; PO; Phase 3, Phase 4
Large Neutral Amino Acid Therapy: Dosed by weight: weight x .5 = total tablets per day; PO; Phase 1, Phase 4; taken with food</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Melatonin at the End of 4 Weeks</title>
          <description>Evaluated for each subject under 4 conditions (washout, LNAA only, Kuvan only and LNAA+Kuvan)</description>
          <population>Participates who completed all phases were measured.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266.9" spread="165.7"/>
                    <measurement group_id="O2" value="205.7" spread="133.1"/>
                    <measurement group_id="O3" value="220.4" spread="138.5"/>
                    <measurement group_id="O4" value="301.2" spread="179.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine 6-sulfatoxymelatonin at the End of 4 Weeks</title>
        <description>Evaluated for each subject under 4 conditions (washout, LNAA only, Kuvan only and LNAA+Kuvan)</description>
        <time_frame>measured every 4 weeks up to 16 weeks</time_frame>
        <population>Participates who completed all phases were measured.</population>
        <group_list>
          <group group_id="O1">
            <title>LNAA</title>
            <description>LNAA
Large Neutral Amino Acid Therapy: Dosed by weight: weight x .5 = total tablets per day; PO; Phase 1, Phase 4; taken with food</description>
          </group>
          <group group_id="O2">
            <title>Washout</title>
            <description>no Kuvan or LNAA or any medical food products. Limited protein intake diet.</description>
          </group>
          <group group_id="O3">
            <title>BH4 (Kuvan)</title>
            <description>Kuvan (BH4): Dosed at 20 mg/kg; PO; Phase 3, Phase 4</description>
          </group>
          <group group_id="O4">
            <title>BH4 and LNAA</title>
            <description>Kuvan: Dosed at 20 mg/kg; PO; Phase 3, Phase 4
Large Neutral Amino Acid Therapy: Dosed by weight: weight x .5 = total tablets per day; PO; Phase 1, Phase 4; taken with food</description>
          </group>
        </group_list>
        <measure>
          <title>Urine 6-sulfatoxymelatonin at the End of 4 Weeks</title>
          <description>Evaluated for each subject under 4 conditions (washout, LNAA only, Kuvan only and LNAA+Kuvan)</description>
          <population>Participates who completed all phases were measured.</population>
          <units>ng/mg Creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="9.0"/>
                    <measurement group_id="O2" value="8.2" spread="4.8"/>
                    <measurement group_id="O3" value="8.6" spread="5.7"/>
                    <measurement group_id="O4" value="13.2" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine Dopamine at the End of 4 Weeks</title>
        <description>Evaluated for each subject under 4 conditions (washout, LNAA only, Kuvan only and LNAA+Kuvan)</description>
        <time_frame>measured every 4 weeks up to 16 weeks</time_frame>
        <population>Participates who completed all phases were measured.</population>
        <group_list>
          <group group_id="O1">
            <title>LNAA</title>
            <description>LNAA
Large Neutral Amino Acid Therapy: Dosed by weight: weight x .5 = total tablets per day; PO; Phase 1, Phase 4; taken with food</description>
          </group>
          <group group_id="O2">
            <title>Washout</title>
            <description>no Kuvan or LNAA or any medical food products. Limited protein intake diet.</description>
          </group>
          <group group_id="O3">
            <title>BH4 (Kuvan)</title>
            <description>Kuvan (BH4): Dosed at 20 mg/kg; PO; Phase 3, Phase 4</description>
          </group>
          <group group_id="O4">
            <title>BH4 and LNAA</title>
            <description>Kuvan: Dosed at 20 mg/kg; PO; Phase 3, Phase 4
Large Neutral Amino Acid Therapy: Dosed by weight: weight x .5 = total tablets per day; PO; Phase 1, Phase 4; taken with food</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Dopamine at the End of 4 Weeks</title>
          <description>Evaluated for each subject under 4 conditions (washout, LNAA only, Kuvan only and LNAA+Kuvan)</description>
          <population>Participates who completed all phases were measured.</population>
          <units>ug/gCreatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.7" spread="26.7"/>
                    <measurement group_id="O2" value="42.6" spread="19.3"/>
                    <measurement group_id="O3" value="46.0" spread="16.8"/>
                    <measurement group_id="O4" value="67.6" spread="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LNAA</title>
          <description>LNAA
Large Neutral Amino Acid Therapy: Dosed by weight: weight x .5 = total tablets per day; PO; Phase 1, Phase 4; taken with food</description>
        </group>
        <group group_id="E2">
          <title>Washout</title>
          <description>no Kuvan or LNAA or any medical food products. Limited protein intake diet.</description>
        </group>
        <group group_id="E3">
          <title>BH4 (Kuvan)</title>
          <description>Kuvan (BH4): Dosed at 20 mg/kg; PO; Phase 3, Phase 4</description>
        </group>
        <group group_id="E4">
          <title>BH4 and LNAA</title>
          <description>Kuvan: Dosed at 20 mg/kg; PO; Phase 3, Phase 4
Large Neutral Amino Acid Therapy: Dosed by weight: weight x .5 = total tablets per day; PO; Phase 1, Phase 4; taken with food</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shoji Yano</name_or_title>
      <organization>USC/Keck School of Medicine</organization>
      <phone>323-226-3816</phone>
      <email>syano@usc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

